Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02333058
Recruitment Status : Active, not recruiting
First Posted : January 7, 2015
Last Update Posted : March 27, 2018
Sponsor:
Collaborators:
Celerion
Syneos Health
Information provided by (Responsible Party):
medac GmbH

Brief Summary:
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a standardised Fludarabine-containing conditioning and to contribute to the current pharmacokinetic model to be able to finally give age (or body surface area) dependent dose recommendations. The treatment regimens given in the protocol MC-FludT.17/M are based on sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic haematopoietic stem cell transplantation of the selected patient population, the risk-benefit assessment is therefore reasonably in favour of the study conduct.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukaemias (ALL) Acute Myeloid Leukaemias (AML) Myelodysplastic Syndromes (MDS) Juvenile Myelomonocytic Leukaemias (JMML) Drug: Treosulfan Phase 2

Detailed Description:

The protocol MC-FludT.17/M is a clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in at least 70 paediatric patients with haematological malignancies (male and female children with haematological malignant diseases as acute lymphoblastic leukaemias (ALL), acute myeloid leukaemias (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukaemias (JMML), requiring myeloablative conditioning treatment with following allo-HSCT).

Treosulfan dose per day is to be calculated by using body surface area (BSA). Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen and the other consists of an intensified regimen with Fludarabine and ThioTEPA.

Freedom from transplant (treatment)-related mortality (TRM), defined as death from any transplant-related cause from the day of first administration of study medication until day +100 after HSCT is the primary objective of the trial.

Moreover, the current pharmacokinetic (PK) model should be contributed to be able to finally give age (or BSA) dependent dose recommendations.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies
Study Start Date : July 2014
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019


Arm Intervention/treatment
Experimental: Treosulfan

Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.

Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.

Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2.

Drug: Treosulfan

Treosulfan dose per day is to be calculated by using BSA:

One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.

Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.

Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2.

Other Names:
  • Treograft®
  • Ovastat®




Primary Outcome Measures :
  1. Freedom from transplant (treatment)-related mortality (TRM) [ Time Frame: from the day of first administration of study medication until day +100 after HSCT ]
    TRM is defined as death from any transplant-related cause


Secondary Outcome Measures :
  1. Engraftment after HSCT [ Time Frame: until engraftment ]

    Engraftment is defined as first of three consecutive days for each of the following four criteria:

    • a leukocyte count of more than 1 x 109/L
    • an absolute neutrophil count (ANC) of more than 0.5 x 109/L
    • a platelet count of at least 20 x 109/L in the absence of platelet transfusion
    • a platelet count of at least 50 x 109/L in the absence of platelet transfusion

  2. Safety including early toxicity until day +100 after HSCT, serious adverse reactions (SARs) until the end of the longer-term follow-up phase [ Time Frame: until 12 months after HSCT ]
    based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

  3. Hepatic sinusoidal obstruction syndrome (HSOS), lung toxicity (CTCAE term pulmonary fibrosis), hepatic toxicity and infections of any CTCAE grade (non-serious and serious) [ Time Frame: until day +100 after HSCT ]
  4. Donor-type chimerism [ Time Frame: on day +28, day +100 and 12 months after HSCT ]
    The incidences of complete donor-type chimerism will be estimated as the number of patients with complete chimerism divided by the total number of patients at risk.

  5. Non relapse mortality (NRM), transplant related mortality (TRM), graft failure rate, incidence of relapse/progression, relapse-free/progression-free survival (RFS/PFS) and overall survival (OS) [ Time Frame: after 12 months after HSCT and until the end of the longer-term follow-up phase ]

    Non-relapse mortality will be defined as the probability of dying in the absence of persisting disease or previous occurrence of relapse/progression or graft failures.

    TRM is defined as the probability of dying from a transplant-related cause. The associated time span is defined as the interval from day 0 to death due to a transplant-related cause.

    The incidence of relapse/progression is defined as the probability of having relapse/progression of the underlying disease.

    Relapse-free/progression-free survival is defined as the time length between day 0 and the date of relapse/progression of the underlying disease or death due to any cause.

    OS after HSCT is defined as the probability of surviving. Survival time is defined as the time period between day 0 and the day of death due to any cause.

    Kaplan-Meier methods will be applied for estimating the probability of these parameters over time.


  6. Incidence and severity of acute (until day +100) and chronic (until 12 months after HSCT) graft versus host disease (aGvHD/cGvHD) [ Time Frame: until 12 months after HSCT ]

    The probability of grade I-IV and grade III-IV aGvHD will be estimated by cumulative incidence rates and summarised for selected time points together with their approximate 90 % confidence intervals.

    As for aGvHD, the probability of cGvHD will be estimated by cumulative incidence rates.


  7. Use of rescue therapies including donor-lymphocyte infusions (DLIs) and further conditioning regimens [ Time Frame: until 12 months after HSCT ]
  8. PK parameters of Treosulfan and its epoxides [ Time Frame: day -6 prior to HSCT ]
    The following PK parameters of Treosulfan and its epoxides will be measured: Clearance (CL); volume of distribution (Vss); terminal elimination rate constant (λz); terminal elimination half-life (t1/2); area under the concentration time curve from time zero to infinity (AUC∞); maximum observed concentration (Cmax, i.e. C end of infusion).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Haematological malignant disease i.e. ALL, AML, MDS or JMML, indicated for allo-HSCT.
  2. Indication for first allo-HSCT or second allo-HSCT due to disease relapse, graft failure, or secondary malignancy after previous HSCT.
  3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as 9/10 or 10/10 allele match after four digit typing in human leucocyte antigens (HLA)-A, B, C, DRB1 and DQB1.
  4. Patients with ALL or AML in complete morphologic remission (blast counts <5 % in BM) and patients with MDS or JMML with blast counts < 20 % in BM at study entry.
  5. Age at time of registration from 28 days to less than 18 years of age.
  6. Lansky (patients aged <16 years) or Karnofsky (patients aged ≥ 16 years) performance score of at least 70 %.
  7. Written informed consent of the parents/ legal guardians and patient's assent/consent according to national regulations.
  8. Females of child-bearing potential or male patients' partners with child-bearing potential must use a highly effective method of contraception (pearl index < 1 %) such as complete sexual abstinence, combined oral contraceptive, hormone intrauterine contraceptive device (IUCD), vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients or male partners during the study and at least 6 months thereafter.
  9. Negative pregnancy test for females of child-bearing potential.

Exclusion Criteria:

  1. Third or later allo-HSCT.
  2. HSCT from haploidentical or umbilical cord blood donor.
  3. Symptomatic involvement of central nervous system (CNS) at study entry.
  4. Treatment with cytotoxic drugs within 10 days prior to day 7.
  5. Obese paediatric patients with body mass index: weight (kg)/[height (m)]² > 30 kg/m².
  6. Solid tumours (e.g. neuroblastoma, peripheral neuroectodermal tumour [PNET], Ewing sarcoma).
  7. Fanconi anaemia and other deoxyribonucleic acid (DNA) breakage repair disorders.
  8. Impaired liver function indicated by Bilirubin > three times the upper limit of normal (ULN) or aspartate aminotransferase/alanine aminotransferase (AST/ALT) > five times ULN, or active infectious hepatitis.
  9. Impaired renal function indicated by estimated glomerular filtration rate ([GFR], according to the Schwartz formula) < 60 mL/min/1,73m2.
  10. Impaired cardiac function: severe cardiac insufficiency indicated by left ventricle ejection fraction (LVEF) < 35 %.
  11. Requirement for supplementary continuous oxygen.
  12. Severe active infection requiring deferral of conditioning.
  13. Human immunodeficiency virus (HIV) positivity.
  14. Known pregnancy, breast feeding.
  15. Known hypersensitivity to Treosulfan and/or Fludarabine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02333058


Locations
Layout table for location information
Austria
St. Anna Children Hospital
Vienna, Austria, A-1090
Czechia
University Hospital Motol, Charles University, Prague
Prague, Czechia, 150-06
Germany
University Clinic Düsseldorf
Düsseldorf, Germany, 40225
University Clinic Erlangen-Nürnberg
Erlangen, Germany, 91054
University Hospital Johann Wolfgang Goethe
Frankfurt, Germany, 60590
University Clinic Hamburg-Eppendorf
Hamburg, Germany, 20246
Medical University Hannover
Hannover, Germany, 30625
University Clinic Heidelberg
Heidelberg, Germany, 69120
University Clinic Jena
Jena, Germany, 07740
University Clinic München
München, Germany, 80804
Univercity Clinic Münster
Münster, Germany, 48129
University Clinic Regensburg
Regensburg, Germany, 93053
University Clinic Ulm
Ulm, Germany, 89075
University Clinic Würzburg
Würzburg, Germany, 97080
Italy
Ospedale Bambino Gesu Roma
Rome, Italy, 00165
Ospedale Infantile Regina Margherita Torino
Turin, Italy, 10126
Poland
Bydgoszcz Medical University
Bydgoszcz, Poland, 85-094
Kraków Medical University
Kraków, Poland, 30-663
Lublin Medical University
Lublin, Poland, 20-093
Wroclaw Medical University
Wroclaw, Poland, 50-368
United Kingdom
Birmingham Children's Hospital
Birmingham, United Kingdom, B4 6NH
Central Manchester University Hospital
Manchester, United Kingdom, M13 9WL
Sheffield Children's Hospital
Sheffield, United Kingdom, S10 2TH
Sponsors and Collaborators
medac GmbH
Celerion
Syneos Health
Investigators
Layout table for investigator information
Principal Investigator: Ajay Vora, MD, Prof. Sheffield Children's Hospital

Additional Information:
Layout table for additonal information
Responsible Party: medac GmbH
ClinicalTrials.gov Identifier: NCT02333058     History of Changes
Other Study ID Numbers: MC-FludT.17/M
First Posted: January 7, 2015    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: March 2018

Keywords provided by medac GmbH:
ALL
AML
MDS
JMML

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myelomonocytic, Juvenile
Hematologic Neoplasms
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Site
Fludarabine
Thiotepa
Treosulfan
Busulfan
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Immunosuppressive Agents